• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 24, 2013

View Archived Issues

FDA 'Nucs' Idenix with '963 Safety Data Request

Idenix Pharmaceuticals Inc. suffered yet another blow in the development of its hepatitis C virus (HCV) drug pipeline, as the FDA requested additional preclinical safety data for IDX20963 ('963), the company's lead uridine nucleotide prodrug. Read More

'No Exit' on Chinese Markets Despite Relaxing of IPO Ban

SHANGHAI, China – Chinese biopharmaceutical companies are unlikely to benefit much from a relaxation in an 8-month-old ban on new initial public offerings (IPOs) or from new draft regulations aimed at improving disclosures and governance. Read More

Targeting Ceramide Could Yield New Antidepressants

Selective serotonin reuptake inhibitors, or SSRIs, increase serotonin signaling in the brain, and they have antidepressant effects, at least in some patients. Read More

'FASN' Your Seat Belt: Series C Funds 3-V Biosciences' Phase I

3-V Biosciences Inc.'s $20 million Series C financing will push the lead cancer product, a fatty acid synthase (FASN) inhibitor, through Phase I trials, while boosting preclinical studies with leads in virology – the research area on which the company was founded in 2007. Read More

Ambrx Enters China, Inks ZMC Deal for Breast Cancer Drug

SHANGHAI, China – In its first China deal, San Diego-based biopharma developer Ambrx Inc. will work with Zhejiang Medicine Co. (ZMC) to develop a new breast cancer drug. Read More

Stock Movers

Read More

Other News To Note

• Bellus Health Inc., of Laval, Quebec, and Thallion Pharmaceuticals Inc., of Dorval, Quebec, said Bellus agreed to acquire Thallion for about $6.3 million in cash, or about 17 cents per share (on a fully diluted basis), subject to certain adjustments, and the issuance of contingent value rights (CVRs). Read More

Clinic Roundup

• Seattle Genetics Inc., of Bothell, Wash., reported data at the International Conference on Malignant Lymphoma in Lugano, Switzerland, including results from a Phase II trial testing PET-adapted sequential therapy with CD30-targeted antibody-drug conjugate Adcetris (brentuximab vedotin), augmented by the ICE chemo regimen (ifosfamide, carboplatin and etoposide), which showed that 79 percent of 33 evaluable patients obtained a complete remission, including 10 patients who achieved PET-normalization (PET-N) following treatment with Adcetris alone and 16 patients who achieved PET-N following the sequential treatment program. Read More

Pharma: Other News To Note

• Pfizer Inc., of New York, said the FDA accepted for review a supplemental new drug application for Xeljanz (tofacitinib citrate) seeking to expand the drug's rheumatoid arthritis (RA) indication to include inhibition of progression of structural damage. The PDUFA date is expected to be in February 2014. Read More

Bench Press: BioWorld Looks at Translational Medicine

Several successful cancer drugs target receptor tyrosine kinases, which phosphorylate proteins to activate them. Now, a group from the Singaporean Agency for Science, Technology and Research has shown that a protein phosphatase may be a useful target for preventing metastasis in triple-negative breast cancer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe